Pharmaceutical composition for treating children leukemia and application thereof

Abstract

The invention provides a pharmaceutical composition for treating children leukemia and application thereof, and relates to the field of pharmaceutical compositions for treating children leukemia. The pharmaceutical composition for treating children leukemia is prepared from the following raw materials: indigo naturalis, airpotato yam rhizome, oldenlandia diffusa, sculellaria barbata, solanum nigrum, radix isatidis, fructus forsythiae, scutellaria baicalensis, salvia miltiorrhiza, angelica sinensis, radix bupleuri and bighead atractylodes rhizome. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 8-10 parts of indigo naturalis, 6-13 parts of airpotato yam rhizome, 16-25 parts of oldenlandia diffusa, 3-10 parts of sculellaria barbata, 9-15 parts of solanum nigrum, 5-10 parts of radix isatidis, 6-12 parts of fructus forsythiae, 15-25 parts of scutellaria baicalensis, 13-18 parts of salvia miltiorrhiza, 3-9 parts of angelica sinensis, 9-18 parts of radix bupleuri and 14-28 parts of bighead atractylodes rhizome. The medicine is beneficial to slow release of alopecia of children during leukemia treatment, prevents psychological problems caused by alopecia during children treatment from affecting the curative effect, and can achieve the effect of soothing the liver by arranging radix bupleuri, so that adverse reactions caused by stimulation of some traditional Chinese medicines to the spleen and the stomach are relieved.

Description

Technical Field

[0001] The present invention relates to the technical field of drug combinations for children with leukemia, and in particular to a drug combination for treating children with leukemia and application thereof. Background Art

[0002] Leukemia is a malignant disease of hematopoietic tissue, also known as "blood cancer". A series of hematopoietic cells, mainly the precursor cells of a series of white blood cells, lose their ability to differentiate and mature, and they proliferate and accumulate in a malignant clonal manner in the bone marrow and other hematopoietic tissues, and invade the liver, spleen, and lymph nodes, eventually infiltrating and destroying tissues and organs throughout the body, inhibiting normal hematopoietic function. Unlike solid tumors, leukemia is not a local growth, but a malignant blood disease that spreads throughout the body and may invade various systems, organs, and tissues.

[0003] Most of the drugs for treating leukemia in the prior art are for adults, and the dosage is only reduced for children. Children taking leukemia drugs may suffer from problems such as hair loss, liver damage, and chronic gastritis. For example, the above side effects may cause psychological problems after recovery, and the appearance and physical condition of children will be affected. The existing therapeutic drugs have not been able to develop different drugs specifically for childhood leukemia, so there is a lack of drugs for treating childhood leukemia. Summary of the invention

[0004] 1. Technical issues to be resolved

[0005] In view of the deficiencies of the prior art, the present invention provides a drug combination for treating childhood leukemia and its application, which solves the problem that the existing therapeutic drugs cannot be developed into different drugs specifically for childhood leukemia.

[0006] (II) Technical solution

[0007] To achieve the above objectives, the present invention is implemented through the following technical scheme: a drug combination for treating childhood leukemia, the drug composition comprising the following raw materials: Indigo naturalis, Dioscorea bulbifera, Oldenlandia diffusa, Scutellaria barbata, Solanum nigrum, Isatis root, Forsythia suspensa, Scutellaria baicalensis, Salvia miltiorrhiza, Angelica sinensis, Bupleurum and Atractylodes macrocephala.

[0008] Preferably, the pharmaceutical composition comprises the following raw materials in parts by weight: 8-10 parts of Indigo Naturalis, 6-13 parts of Dioscorea Bulbifera, 16-25 parts of Oldenlandia Diffusa, 3-10 parts of Scutellaria Barbata, 9-15 parts of Solanum nigrum, 5-10 parts of Isatis Indigotica, 6-12 parts of Forsythia, 15-25 parts of Scutellaria Baicalensis, 13-18 parts of Salvia Miltiorrhiza, 3-9 parts of Angelica Sinensis, 9-18 parts of Bupleurum and 14-28 parts of Atractylodes Macrocephala.

[0009] Preferably, the pharmaceutical composition comprises the following raw materials in parts by weight: 8 parts of Indigo Naturalis, 6 parts of Dioscorea Bulbifera, 16 parts of Oldenlandia Diffusa, 3 parts of Scutellaria Barbata, 9 parts of Solanum nigrum, 5 parts of Isatis Indigotica, 6 parts of Forsythia suspensa, 15 parts of Scutellaria baicalensis, 13 parts of Salvia miltiorrhiza, 3 parts of Angelica sinensis, 9 parts of Bupleurum and 14 parts of Atractylodes macrocephala.

[0010] Preferably, the pharmaceutical composition comprises the following raw materials in parts by weight: 9 parts of Indigo Naturalis, 8 parts of Dioscorea Bulbifera, 18 parts of Oldenlandia Diffusa, 5 parts of Scutellaria Barbata, 12 parts of Solanum nigrum, 7 parts of Isatis Indigotica, 8 parts of Forsythia suspensa, 17 parts of Scutellaria baicalensis, 15 parts of Salvia miltiorrhiza, 5 parts of Angelica sinensis, 12 parts of Bupleurum and 16 parts of Atractylodes macrocephala.

[0011] Preferably, the pharmaceutical composition comprises the following raw materials in parts by weight: 10 parts of Indigo Naturalis, 10 parts of Dioscorea Bulbifera, 22 parts of Oldenlandia Diffusa, 7 parts of Scutellaria Barbata, 15 parts of Solanum nigrum, 10 parts of Isatis Indigotica, 10 parts of Forsythia suspensa, 20 parts of Scutellaria baicalensis, 18 parts of Salvia miltiorrhiza, 8 parts of Angelica sinensis, 15 parts of Bupleurum and 20 parts of Atractylodes macrocephala.

[0012] Preferably, the pharmaceutical composition comprises the following raw materials in parts by weight: 10 parts of Indigo Naturalis, 13 parts of Dioscorea Bulbifera, 25 parts of Oldenlandia Diffusa, 10 parts of Scutellaria Barbata, 15 parts of Solanum nigrum, 10 parts of Isatis Indigotica, 12 parts of Forsythia suspensa, 25 parts of Scutellaria baicalensis, 18 parts of Salvia miltiorrhiza, 9 parts of Angelica sinensis, 18 parts of Bupleurum and 28 parts of Atractylodes macrocephala.

[0013] A method for preparing a medicine for treating childhood leukemia, wherein the steps of preparing the Dioscorea bulbifera include the following:

[0014] Step 1: Cleaning: Remove the stems and leaves from the excavated Dioscorea bulbifera tubers and wash away the soil to remove impurities and dirt;

[0015] Step 2: Slice: Cut the washed Dioscorea bulbifera tubers into slices of a certain thickness, 1 to 1.5 cm thick, for easy drying and subsequent use;

[0016] Step 3: Drying: Sun-dry or oven-dry the sliced ​​radix scutellariae to remove moisture;

[0017] Step 4: Grinding: Grind the dried flaky yellow bud into powder;

[0018] Step 5: Mixing: The ground Dioscorea bulbifera is mixed with red dates, and the mixing ratio of Dioscorea bulbifera to red dates is 1:0.5.

[0019] A combination of drugs for treating childhood leukemia.

[0020] (III) Beneficial effects

[0021] The present invention provides a drug combination for treating childhood leukemia and its application. It has the following beneficial effects:

[0022] 1. The present invention adds: Chinese angelica, bupleurum and atractylodes. Chinese angelica has the effects of nourishing blood, regulating menstruation and relieving pain. It is suitable for hair loss caused by insufficient qi and blood, and can help to relieve the hair loss problem of children during leukemia treatment, prevent hair loss from affecting the treatment psychological problems of children, and can achieve the effect of soothing the liver by setting bupleurum, reduce the damage of targeted drugs to the liver, and improve the quality of life of patients, thereby improving children's tolerance to the liver during the treatment process, and preventing the side effect of treatment caused by malnutrition due to inability to eat during the treatment of children.

[0023] 2. The present invention adds: Indigo Naturalis, Dioscorea Bulbifera, Oldenlandia Diffusa and Scutellaria Barbata. The combination of the drugs has the effects of clearing away heat and detoxicating, cooling blood and removing spots, and can be used to relieve the symptoms of leukemia. Dioscorea Bulbifera can clear the liver and improve eyesight, resolve phlegm and relieve cough, and has a therapeutic effect on leukemia. Oldenlandia Diffusa has an anti-tumor effect, and the combined use can be used for auxiliary treatment of leukemia and other tumors. Scutellaria Barbata has the effects of clearing away heat and detoxicating, promoting blood circulation and removing blood stasis, and is also suitable for the treatment of leukemia. The combination of the drugs can increase the clearance of leukemia cells and increase the improvement of the disease.

[0024] 3. The present invention adds: Dioscorea bulbifera, which has a bitter taste in the drug combination ingredients. Adults can resist the bitterness in the drug, but when treating children, the bitterness of the drug will affect the coordinated treatment of the drug and will also cause resistance. Therefore, red dates are added in the preparation process of Dioscorea bulbifera. Red dates are considered to have a sweet taste in traditional Chinese medicine theory, which can alleviate the bitterness or other irritating taste of some traditional Chinese medicines and make the traditional Chinese medicines easier to take. At the same time, red dates also have the effects of tonifying the middle and replenishing qi, nourishing blood and calming the nerves. Adding red dates can enhance the tonic effect of traditional Chinese medicines and can increase the blood-nourishing effect in leukemia drugs. In addition, red dates have a certain protective effect on the spleen and stomach, and can reduce the occurrence of adverse reactions of some traditional Chinese medicines to the spleen and stomach. DETAILED DESCRIPTION

[0025] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0026] Embodiment 1:

[0027] The embodiment of the present invention provides a drug combination for treating childhood leukemia. The drug composition comprises the following raw materials: Indigo naturalis, Dioscorea bulbifera, Oldenlandia diffusa, Scutellaria barbata, Solanum nigrum, Radix Isatidis, Fructus Forsythiae, Radix Scutellariae, Salvia miltiorrhizae, Angelica sinensis, Radix Bupleuri and Atractylodes macrocephala.

[0028] The pharmaceutical composition comprises the following raw materials: indigo naturalis, radix dioscoreae, oldenlandia diffusa, scutellaria barbata, solanum nigrum, isatis root, forsythia, scutellaria baicalensis, salvia miltiorrhiza, angelica sinensis, bupleurum and atractylodes macrocephala. The pharmaceutical composition comprises the following raw materials in parts by weight: 8 parts of indigo naturalis, 6 parts of radix dioscoreae, 16 parts of oldenlandia diffusa, 3 parts of scutellaria barbata, 9 parts of solanum nigrum, 5 parts of isatis root, 6 parts of forsythia, 15 parts of scutellaria baicalensis, 13 parts of salvia miltiorrhiza, 3 parts of angelica sinensis, 9 parts of bupleurum and 14 parts of atractylodes macrocephala.

[0029] A method for preparing a medicine for treating childhood leukemia, wherein the steps of preparing the Dioscorea bulbifera include the following:

[0030] Step 1: Cleaning: Remove the stems and leaves from the excavated Dioscorea bulbifera tubers and wash away the soil to remove impurities and dirt;

[0031] Step 2: Slice: Cut the washed Dioscorea bulbifera tubers into slices of a certain thickness, 1 to 1.5 cm thick, for easy drying and subsequent use;

[0032] Step 3: Drying: Sun-dry or oven-dry the sliced ​​radix scutellariae to remove moisture;

[0033] Step 4: Grinding: Grind the dried flaky yellow bud into powder;

[0034] Step 5: Mixing: The ground Dioscorea bulbifera is mixed with red dates, and the mixing ratio of Dioscorea bulbifera to red dates is 1:0.5.

[0035] A combination of drugs for treating childhood leukemia.

[0036] Embodiment 2:

[0037] The difference between this embodiment and embodiment 1 is that the pharmaceutical composition comprises the following raw materials: Indigo naturalis, Dioscorea bulbifera, Oldenlandia diffusa, Scutellaria barbata, Solanum nigrum, Radix Isatidis, Fructus Forsythiae, Scutellaria baicalensis, Salvia miltiorrhiza, Angelica sinensis, Bupleurum chinense and Atractylodes macrocephala, and the pharmaceutical composition comprises the following raw materials in parts by weight: 9 parts of Indigo naturalis, 8 parts of Dioscorea bulbifera, 18 parts of Oldenlandia diffusa, 5 parts of Scutellaria barbata, 12 parts of Solanum nigrum, 7 parts of Radix Isatidis, 8 parts of Fructus Forsythiae, 17 parts of Scutellaria baicalensis, 15 parts of Salvia miltiorrhiza, 5 parts of Angelica sinensis, 12 parts of Bupleurum chinense and 16 parts of Atractylodes macrocephala.

[0038] A method for preparing a medicine for treating childhood leukemia, wherein the steps of preparing the Dioscorea bulbifera include the following:

[0039] Step 1: Cleaning: Remove the stems and leaves from the excavated Dioscorea bulbifera tubers and wash away the soil to remove impurities and dirt;

[0040] Step 2: Slice: Cut the washed Dioscorea bulbifera tubers into slices of a certain thickness, 1.5 cm thick, for easy drying and subsequent use;

[0041] Step 3: Drying: Sun-dry or oven-dry the sliced ​​radix scutellariae to remove moisture;

[0042] Step 4: Grinding: Grind the dried flaky yellow bud into powder;

[0043] Step 5: Mixing: The ground Dioscorea bulbifera is mixed with red dates, and the mixing ratio of Dioscorea bulbifera to red dates is 1:0.5.

[0044] Embodiment three:

[0045] The difference between this embodiment and embodiment 1 is that the pharmaceutical composition comprises the following raw materials: Indigo naturalis, Dioscorea bulbifera, Oldenlandia diffusa, Scutellaria barbata, Solanum nigrum, Radix Isatidis, Fructus Forsythiae, Baicalin Scutellariae, Salvia miltiorrhizae, Angelica sinensis, Radix Bupleuri and Atractylodes macrocephala, and the pharmaceutical composition comprises the following raw materials in parts by weight: 10 parts of Indigo naturalis, 10 parts of Dioscorea bulbifera, 22 parts of Oldenlandia diffusa, 7 parts of Scutellaria barbata, 15 parts of Solanum nigrum, 10 parts of Radix Isatidis, 10 parts of Fructus Forsythiae, 20 parts of Scutellariae, 18 parts of Salvia miltiorrhizae, 8 parts of Angelica sinensis, 15 parts of Radix Bupleuri and 20 parts of Atractylodes macrocephala.

[0046] A method for preparing a medicine for treating childhood leukemia, wherein the steps of preparing the Dioscorea bulbifera include the following:

[0047] Step 1: Cleaning: Remove the stems and leaves from the excavated Dioscorea bulbifera tubers and wash away the soil to remove impurities and dirt;

[0048] Step 2: Slice: Cut the washed Dioscorea bulbifera tubers into slices of a certain thickness, 1.5 cm thick, for easy drying and subsequent use;

[0049] Step 3: Drying: Sun-dry or oven-dry the sliced ​​radix scutellariae to remove moisture;

[0050] Step 4: Grinding: Grind the dried flaky yellow bud into powder;

[0051] Step 5: Mixing: The ground Dioscorea bulbifera is mixed with red dates, and the mixing ratio of Dioscorea bulbifera to red dates is 1:0.5.

[0052] Embodiment 4:

[0053] The difference between this embodiment and embodiment 1 is that the pharmaceutical composition comprises the following raw materials: Indigo naturalis, Dioscorea bulbifera, Oldenlandia diffusa, Scutellaria barbata, Solanum nigrum, Radix Isatidis, Fructus Forsythiae, Scutellaria baicalensis, Salvia miltiorrhiza, Angelica sinensis, Radix Bupleuri and Atractylodes macrocephala, and the pharmaceutical composition comprises the following raw materials in parts by weight: 10 parts of Indigo naturalis, 13 parts of Dioscorea bulbifera, 25 parts of Oldenlandia diffusa, 10 parts of Scutellaria barbata, 15 parts of Solanum nigrum, 10 parts of Radix Isatidis, 12 parts of Fructus Forsythiae, 25 parts of Scutellaria baicalensis, 18 parts of Salvia miltiorrhiza, 9 parts of Angelica sinensis, 18 parts of Radix Bupleuri and 28 parts of Atractylodes macrocephala.

[0054] A method for preparing a medicine for treating childhood leukemia, wherein the steps of preparing the Dioscorea bulbifera include the following:

[0055] Step 1: Cleaning: Remove the stems and leaves from the excavated Dioscorea bulbifera tubers and wash away the soil to remove impurities and dirt;

[0056] Step 2: Slice: Cut the washed Dioscorea bulbifera tubers into slices of a certain thickness, 1.5 cm thick, for easy drying and subsequent use;

[0057] Step 3: Drying: Sun-dry or oven-dry the sliced ​​radix scutellariae to remove moisture;

[0058] Step 4: Grinding: Grind the dried flaky yellow bud into powder;

[0059] Step 5: Mixing: The ground Dioscorea bulbifera is mixed with red dates, and the mixing ratio of Dioscorea bulbifera to red dates is 1:0.5.

[0060] Comparative example: An embodiment of the present invention provides a drug combination for treating childhood leukemia, comprising the following preparation raw materials: Indigo Naturalis, Dioscorea Bulbifera, Oldenlandia Diffusa, Scutellaria Barbata, Solanum nigrum, Radix Isatidis, Fructus Forsythiae, Baical Skullcap Root, Salvia Miltiorrhiza, Angelica Sinensis, Radix Bupleuri and Atractylodes Macrocephala, and the weight proportions are: 8-10 parts of Indigo Naturalis, 6-13 parts of Dioscorea Bulbifera, 16-25 parts of Oldenlandia Diffusa, 3-10 parts of Scutellaria Barbata, 9-15 parts of Solanum nigrum, 5-10 parts of Radix Isatidis, 6-12 parts of Fructus Forsythiae, 15-25 parts of Scutellaria Baicalensis, 13-18 parts of Salvia Miltiorrhiza, 3-9 parts of Angelica Sinensis, 9-18 parts of Radix Bupleuri and 14-28 parts of Atractylodes Macrocephala.

[0061] The leukemia drugs prepared in Example 1, Example 2, Example 3, Example 4 and the comparative example were used respectively, and the conditions during use were recorded.

[0062] The results are shown in Table 1:

[0063] Table 1

[0064]

[0065] It can be seen from Table 1 that the addition of different Angelica sinensis, Bupleurum chinense and Atractylodes macrocephala raw materials in Example 1, Example 2, Example 3 and Example 4 increases the effect of the preparation of leukemia drugs.

[0066] While embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the invention, and that the scope of the invention is limited by the appended claims and their equivalents.

Claims

1. A drug combination for treating childhood leukemia, characterized in that: The medicine composition comprises the following raw materials: indigo naturalis, rhizoma dioscoreae, herba hedyotis diffusae, scutellaria barbata, solanum nigrum, root of isatis indigotica, forsythia suspensa, scutellaria baicalensis, salvia miltiorrhiza, angelica sinensis, radix bupleuri and atractylodes macrocephala.

2. A drug combination for treating childhood leukemia according to claim 1, characterized in that: The pharmaceutical composition comprises the following raw materials in parts by weight: 8-10 parts of Indigo Naturalis, 6-13 parts of Dioscorea Bulbifera, 16-25 parts of Hedyotis Diffusa, 3-10 parts of Scutellaria Barbata, 9-15 parts of Solanum nigrum, 5-10 parts of Isatis Radix, 6-12 parts of Forsythia, 15-25 parts of Scutellaria Baicalensis, 13-18 parts of Salvia miltiorrhiza, 3-9 parts of Angelica sinensis, 9-18 parts of Bupleurum and 14-28 parts of Atractylodes macrocephala.

3. A drug combination for treating childhood leukemia according to claim 1, characterized in that: The pharmaceutical composition comprises the following raw materials in parts by weight: 8 parts of Indigo Naturalis, 6 parts of Dioscorea Bulbifera, 16 parts of Hedyotis Diffusa, 3 parts of Scutellaria Barbata, 9 parts of Solanum nigrum, 5 parts of Isatis Indigotica, 6 parts of Forsythia suspensa, 15 parts of Scutellaria baicalensis, 13 parts of Salvia miltiorrhiza, 3 parts of Angelica sinensis, 9 parts of Bupleurum and 14 parts of Atractylodes macrocephala.

4. A drug combination for treating childhood leukemia according to claim 1, characterized in that: The pharmaceutical composition comprises the following raw materials in parts by weight: 9 parts of Indigo Naturalis, 8 parts of Dioscorea Bulbifera, 18 parts of Hedyotis Diffusa, 5 parts of Scutellaria Barbata, 12 parts of Solanum nigrum, 7 parts of Isatis Indigotica, 8 parts of Forsythia suspensa, 17 parts of Scutellaria baicalensis, 15 parts of Salvia miltiorrhiza, 5 parts of Angelica sinensis, 12 parts of Bupleurum and 16 parts of Atractylodes macrocephala.

5. A drug combination for treating childhood leukemia according to claim 1, characterized in that: The pharmaceutical composition comprises the following raw materials in parts by weight: 10 parts of Indigo Naturalis, 10 parts of Dioscorea Bulbifera, 22 parts of Hedyotis Diffusa, 7 parts of Scutellaria Barbata, 15 parts of Solanum nigrum, 10 parts of Isatis Radix, 10 parts of Forsythiae, 20 parts of Scutellariae Baicalensis, 18 parts of Salvia miltiorrhiza, 8 parts of Angelica sinensis, 15 parts of Bupleurum and 20 parts of Atractylodes macrocephala.

6. A drug combination for treating childhood leukemia according to claim 1, characterized in that: The pharmaceutical composition comprises the following raw materials in parts by weight: 10 parts of Indigo Naturalis, 13 parts of Dioscorea Bulbifera, 25 parts of Hedyotis Diffusa, 10 parts of Scutellaria Barbata, 15 parts of Solanum nigrum, 10 parts of Isatis Radix, 12 parts of Forsythia, 25 parts of Scutellaria Baicalensis, 18 parts of Salvia miltiorrhiza, 9 parts of Angelica sinensis, 18 parts of Bupleurum and 28 parts of Atractylodes macrocephala.

7. A method for preparing a drug for treating childhood leukemia, based on a drug combination for treating childhood leukemia according to any one of claims 1 to 6, characterized in that: The steps of preparing the Dioscorea bulbifera include the following: Step 1: Cleaning: Remove the stems and leaves from the excavated Dioscorea bulbifera tubers and wash away the soil to remove impurities and dirt; Step 2: Slice: Cut the washed Dioscorea bulbifera tubers into slices of a certain thickness, 1 to 1.5 cm thick, for easy drying and subsequent use; Step 3: Drying: Sun-dry or oven-dry the sliced ​​radix scutellariae to remove moisture; Step 4: Grinding: Grind the dried flaky yellow bud into powder; Step 5: Mixing: The ground Dioscorea bulbifera is mixed with red dates, and the mixing ratio of Dioscorea bulbifera to red dates is 1:0.

5.

8. Use of a drug combination for treating childhood leukemia as described in any one of claims 1 to 6.

Images